Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
- Associated Therapies
- -
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 163
- Registration Number
- NCT00558103
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT00540943
- Locations
- 🇫🇷
GSK Investigational Site, Toulouse, France
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00516672
- Locations
- 🇯🇵
GSK Investigational Site, Saitama, Japan
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT00387764
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
- Conditions
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 86
- Registration Number
- NCT00388076
- Locations
- 🇺🇸
GSK Investigational Site, Nashville, Tennessee, United States
Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)
- Conditions
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00387387
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, Surrey, United Kingdom
Study To Assess Long Term Safety Of Pazopanib
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 188
- Registration Number
- NCT00387205
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT00370513
- Locations
- 🇨🇳
GSK Investigational Site, Taipei, Taiwan
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2012-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT00367679
- Locations
- 🇪🇸
GSK Investigational Site, Barcelona, Spain
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
- Conditions
- Interventions
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT00358384
- Locations
- 🇫🇷
GSK Investigational Site, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.